摘要
Abstract
Objective:To evaluate docetaxel combination bicalutamide monotherapy treatment of advanced prostate cancer clinical efficacy and safety. Method:Selection on June 1,2009 to June 1,2010,the author’s hospital treated the clinical data of 40 patients with prostate cancer were retrospectively analyzed,as the case to the more than carew amine combining west he treatment,observe its efficacy and safety.Result:Treatment period,40 patients were followed up for 3-48 months,22 cases,8 cases there was pain relief and progress in 10 cases.40 patients after treatment,began to PSA are falling,followed up for 1 year,28 cases dropped to normal blood PSA,2 years,20 cases in stable condition,6 cases fell dissatisfied or bounce,to switch to other treatments. Until December 2012,20 cases survived,the remaining 12 cases died of prostate cancer progression,8 cases died of other diseases.Hot flashes are shown during treatment of 10 cases,male breast tenderness in 5 cases,2 cases of breast development,gastrointestinal adverse reactions (nausea,vomiting) in 2 cases,bone marrow suppression in 2 cases,19 cases without adverse reaction.Conclusion:Docetaxel combined bicalutamide treatment of advanced prostate cancer,a significant effect,worthy of promotion.关键词
前列腺癌/多西他赛/内分泌/比卡鲁胺Key words
Prostate cancer/Docetaxel/Endocrine therapy/Bicalutamide分类
医药卫生
